Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lipocine (LPCN) Current Assets (2016 - 2025)

Lipocine's Current Assets history spans 14 years, with the latest figure at $15.9 million for Q3 2025.

  • For Q3 2025, Current Assets fell 22.31% year-over-year to $15.9 million; the TTM value through Sep 2025 reached $15.9 million, down 22.31%, while the annual FY2024 figure was $22.3 million, 2.36% down from the prior year.
  • Current Assets reached $15.9 million in Q3 2025 per LPCN's latest filing, down from $18.4 million in the prior quarter.
  • In the past five years, Current Assets ranged from a high of $47.2 million in Q2 2021 to a low of $15.9 million in Q3 2025.
  • Average Current Assets over 5 years is $30.7 million, with a median of $27.1 million recorded in 2023.
  • Peak YoY movement for Current Assets: soared 119.14% in 2021, then plummeted 33.03% in 2023.
  • A 5-year view of Current Assets shows it stood at $46.4 million in 2021, then fell by 26.4% to $34.1 million in 2022, then tumbled by 33.03% to $22.9 million in 2023, then decreased by 2.36% to $22.3 million in 2024, then fell by 28.63% to $15.9 million in 2025.
  • Per Business Quant, the three most recent readings for LPCN's Current Assets are $15.9 million (Q3 2025), $18.4 million (Q2 2025), and $20.3 million (Q1 2025).